As a trusted leader in the immunotherapy field, the Society for Immunotherapy of Cancer (SITC) collaborates with other groups to contribute toward high-quality educational programming on tumor immunology and cancer immunotherapy.
Through these educational partnerships, SITC is able to bring high quality, timely cancer immunotherapy information to learners around the world from a variety of backgrounds including scientists, academicians, researchers, clinicians, government representatives and industry leaders.
SITC offers various levels of support for the programs below, such as sharing information about unique programs, providing expert speakers to enhance programming and organizing immunotherapy sessions at relevant association meetings.
If you'd like to get in touch with the society to discuss Collaborative Education Programs, please email the SITC Live Education Department at Education@sitcancer.org.
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Regarding lymphatic endothelial cell-related cancer and post-transplant recipients. Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) evades immune killing of tumor cells by relying on its immunomodulatory viral antigens. Organ donors in high seroprevalence ...
There is likely an unpublished cohort of patients throughout the world who were treated with ipilimumab prior to the introduction of nivolumab/ipilimumab combination and achieved an either complete remission or partial remission. These patients then ...
The case report presented here on advanced melanoma, in an elderly patient on page 810, indicates that despite of lack of prior ipilimumab treatment it cannot be excluded that subsequent observed astonishing treatment with nivolumab can partially be due ...
An article of Larking et al published in JCO 2017 showed evidence of the CheckMate 037 in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy, in which they conclude that - and I quote- : "nivolumab treatment after ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org